Table 3 Candidate immunotherapy according to genomic findings in gastric adenocarcinoma patients included in this study.

From: Socioeconomic disparities and the genomic landscape of gastric cancer

SES

Biomarker findings

Drugs with clinical relevance in gastric cancer

Drugs with clinical relevance in other tumor types

LSES

Microsatellite status-MSI-High

Nivolumab, Pembrolizumab, Dostarlimab*

Atezolizumab, Avelumab, Cemiplimab, Dostarlimab*, Durvalumab

TMB-high

Nivolumab, Pembrolizumab, Dostarlimab*

Atezolizumab, Avelumab, Cemiplimab, Dostarlimab*, Durvalumab, Nivolumab+Ipilimumab

MHSES

Microsatellite status-MSI-High

Nivolumab, Dostarlimab*, Pembrolizumab

Atezolizumab, Avelumab, Cemiplimab, Durvalumab

TMB-high

Nivolumab, Pembrolizumab, Dostarlimab*

Atezolizumab, Avelumab, Cemiplimab, Durvalumab, Nivolumab, Nivolumab+Ipilimumab

  1. Potential therapies for each SES group, which were based on patient biomarker findings to identify drugs with clinical relevance in gastric cancer, as well as drugs with clinical relevance in other types of cancer.
  2. *FDA-approved for the treatment of solid tumors, including gastric cancers.
Back to article page